<DOC>
	<DOCNO>NCT01587040</DOCNO>
	<brief_summary>Primary Objective : The purpose study determine long term safety tolerability SAR245408 SAR245409 monotherapy part combination regimen subject benefit treatment .</brief_summary>
	<brief_title>Open Label Treatment Extension Study With SAR245408 SAR245409 Monotherapy Combination Regimen</brief_title>
	<detailed_description>The duration study individual subject include : 1 . Baseline assessment : within 7 day prior first dose IMP . 2 . Study treatment period ( ) : Subjects start study treatment begin initiation extension period base length prior therapy SAR245408 SAR245409 - &lt; 2 cycle , start initiation period ; subject must complete visit initiation period move extension period . - ≥2 cycle , start extension period ; duration extension period unlimited . - Subjects take SAR245408 SAR245409 daily dose high establish dose SAR245408 SAR245409 , respectively , parental study enter study Day 1 initiation period . - Subjects dose interrupted parental study fulfill parental protocol criterion restart IMP treatment enter treatment-extension study Day 1 initiation period . - Subjects fulfill parental study criterion IMP treatment continuation ongoing Grade 2 AE ( ) enter treatment-extension study Day 1 initiation period . Subjects may continue receive study treatment disease progression , unacceptable toxicity , withdrawal consent , commercial supply SAR245408 SAR245409 available outside clinical trial 3 . Follow-up assessment : 23 37 day last dose IMP .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : I 01 . Males female enrol Phase 1 Phase 2 study SAR245408 SAR245409 monotherapy combination regimens complete data collection primary endpoint ( ) parental study treat beyond parental study cutoff meet criterion continue treat per parental protocol . I 02 . All sexually active subject ( male female ) must agree continue use accept method barrier contraception ( ie , condom ) course study 3 month discontinuation study treatment . For woman childbearing potential men father child , second method contraception addition barrier method recommend . Hormonal contraception avoid subject take SAR245408 due possible drugdrug interaction . I 03 . Female subject childbearing potential must negative pregnancy test baseline . Females childbearing potential define sexually mature woman without prior hysterectomy evidence menses past 12 month . However , woman amenorrheic 12 month still consider childbearing potential amenorrhea possibly due cause , include prior chemotherapy , antiestrogens , ovarian suppression Exclusion criterion : E 01 . The subject discontinue parental study due toxicity E 02 . Ongoing Grade 3 high Adverse Event ( AE ) E 03 . Ongoing Serious Adverse Event ( SAE ) E 04 . Subjects ongoing dose interruption reason unless subject fulfills criteria parental protocol restart IMP . In case subject start treatmentextension study Day 1 initiation period E 05 . The subject follow laboratory value ≥ Common Terminology Adverse Events ( CTCAE ) Grade 3 Absolute neutrophil count ( ANC ) , Platelet count , Hemoglobin , Bilirubin , Serum creatinine calculate creatinine clearance , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , Fasting plasma glucose ( FPG ) , Prothrombin time/international normalize ratio ( PT/INR ) activate partial thromboplastin time ( aPTT ) E 06 . The subject baseline correct QT interval ( QTc ) &gt; 481 msec subject QTc interval increase ≥ 60 msec parental protocol baseline absolute value &gt; 470 msec E 07 . The subject know allergy hypersensitivity component study treatment formulation ( ) E 08 . The subject pregnant breastfeed The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>